Skip NavigationSkip to Content

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

  1. Author:
    Bergamaschi, Cristina
    Watson, Dennis
    Valentin, Antonio
    Bear, Jenifer
    Peer, Cody J
    Figg, William D
    Felber, Barbara
    Pavlakis, George
  2. Author Address

    Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA., Clinical Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA. Electronic address: george.pavlakis@nih.gov.,
    1. Year: 2018
    2. Date: Aug
    3. Epub Date: 2018 05 07
  1. Journal: Cytokine
    1. 108
    2. Pages: 213-224
  2. Type of Article: Article
  3. ISSN: 1043-4666
  1. Abstract:

    The common ?-chain cytokine interleukin-15 (IL-15) plays a significant role in regulating innate and adaptive lymphocyte homeostasis and can stimulate anti-tumor activity of leukocytes. We have previously shown that the circulating IL-15 in the plasma is the heterodimeric form (hetIL-15), produced upon co-expression of IL-15 and IL-15 Receptor alpha (IL-15Ra) polypeptides in the same cell, heterodimerization of the two chains and secretion. We investigated the pharmacokinetic and pharmacodynamic profile and toxicity of purified human hetIL-15 cytokine upon injection in rhesus macaques. We compared the effects of repeated hetIL-15 administration during a two-week dosing cycle, using different subcutaneous dosing schemata, i.e. fixed doses of 0.5, 5 and 50?µg/kg or a doubling step-dose scheme ranging from 2 to 64?µg/kg. Following a fixed-dose regimen, dose-dependent peak plasma IL-15 levels decreased significantly between the first and last injection. The trough plasma IL-15 levels measured at 48?h after injections were significantly higher after the first dose, compared to subsequent doses. In contrast, following the step-dose regimen, the systemic exposure increased by more than 1 log between the first injection given at 2?µg/kg and the last injection given at 64?µg/kg, and the trough levels were comparable after each injection. Blood lymphocyte cell count, proliferation, and plasma IL-18 levels peaked at day 8 when hetIL-15 was provided at fixed doses, and at the end of the cycle following a step-dose regimen, suggesting that sustained expansion of target cells requires increasing doses of cytokine. Macaques treated with a 50?µg/kg dose showed moderate and transient toxicity, including fever, signs of capillary leak syndrome and renal dysfunction. In contrast, these effects were mild or absent using the step-dose regimen. The results provide a new method of optimal administration of this homeostatic cytokine and may have applications for the delivery of other cytokines. Published by Elsevier Ltd.

    See More

External Sources

  1. DOI: 10.1016/j.cyto.2018.01.011
  2. PMID: 29402721
  3. WOS: 000435058900030
  4. PII : S1043-4666(18)30011-5

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel